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Introduction
Discovered by pure chance in patients recovering from chemo-
therapy almost 45 years ago1, the phenomenon of hematopoietic 
stem cell (HSC) mobilization has transformed the clinical prac-
tice of HSC transplantation2. It has further extended to indications 
beyond HSC collection, including mobilization-based chemo-
sensitization, conditioning, and gene therapeutic approaches, 
which are areas of intensive research. Better understanding of 
the pathways governing HSC trafficking can provide important 
insights into how stem cell localization within the bone marrow 
(BM) is regulated, which explains a continued need for basic 
research on mobilization to define the underlying molecular and 
cellular mechanisms.
In mammals, the first definitive HSCs arise in several intra and 
extraembryonic tissues from which they first migrate into the 
fetal liver3,4. Following expansion in the fetal liver, HSCs con-
tinue their journey towards the BM, where the overwhelming 
majority of adult HSCs are subsequently found in their unique, 
specialized environments, the BM niches5,6. Interestingly, 
despite the dramatically reduced migratory activity upon BM 
colonization, a small fraction of adult HSCs can be found in the 
peripheral circulation at any given time7–9. Even though random 
leakiness of BM retention pathways cannot be excluded as a 
cause, the regularity of this physiological HSC egress10–12 
implies a biological function. The number of HSCs in the circu-
lation at steady state can be substantially augmented by a wide 
variety of endogenous and exogenous stimuli such as growth 
factors13–20, chemotherapy1,21–23, chemokines24–27, chemokine and 
integrin receptor agonists and antagonists28–31, bioactive lipids32,33, 
exercise34,35, infection, and inflammation36,37 (Figure 1). This 
enforced egress of HSCs into peripheral blood is called 
Figure 1. Mobilization stimuli. A wide variety of stimuli that lead to increased numbers of circulating hematopoietic stem cells (HSCs) 
have been identified, including but not limited to growth factors (cytokines17, granulocyte colony-stimulating factor [G-CSF]19,38, granulocyte-
macrophage colony-stimulating factor [GM-CSF]20, stem cell factor [SCF]18,39,40, FLT3 ligand [FLT3L]40–42, thrombopoietin [TPO]15,16,40, 
angiopoietin [Angpt]43,44, vascular endothelial growth factor [VEGF]43–45, and interleukins [ILs] -146, -347,48, -649, -750, -1251, -1752, and -3353,54), 
chemotherapy-induced myeloid rebound1,23,55, chemokines (CXCL12 and analogs27,56, Gro-α57, -β26,57–59, and -γ57, and IL-824,25,60), chemokine 
receptor antagonists (CXCR4 antagonists61,62,63 and inhibitors of the intracellular mediator of CXCR4 signaling, the small Rho GTPase Rac164,65), 
bioactive lipids (sphingosine-1 phosphate [S1P]66,67 and ceramide-1 phosphate [C1P]66,67) and bacterial toxins36,68,69 (lipopolysaccharide 
[LPS]37,70 and pertussis toxin [PTX]71–74), proteases (trypsin75, matrix metalloprotease 9 [MMP9]58,76, CD2677,78, cathepsin G79, and neutrophil 
elastase79) and adenosine receptor agonists (defibrotide)80,81, inhibitors of adhesive cell interactions82 (VLA428,29,83 and VLA4/VLA984 inhibitors, 
VCAM185, and CD4486,87 blockers) and ephrin A3 receptor antagonists88, polymeric sugar molecules (dextran89, fucoidan89,90, Betafectin 
PGG-Glucan91, and glycosaminoglycan [GAG] mimetics92), and prostaglandin inhibitors93. For the majority of the listed stimuli, a direct or 
indirect targeting of CXCR4 (green) or VLA4 (blue) signaling or both (red) has been documented. On the systemic level, the time of day10,11,94, 
stress95,96 and exercise97–100, trauma and tissue damage101–103, infection104 and inflammation105,106, coagulation107–109 and complement110–113 
cascade along with cortisol94,114 and the central114 as well as the sympathetic nervous system (SNS)115 have been shown to affect HSC 
egress out of the bone marrow (BM) into the peripheral blood. In sharp contrast to the diversity of mobilizing agents discovered and tested 
in preclinical models, only G-CSF alone (healthy donors) or in conjunction with chemotherapy and plerixafor (patients) is being used in the 
clinic. CNS, central nervous system.
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mobilization. While the function of homeostatically circulat-
ing HSCs remains enigmatic, pharmacologically induced HSC 
egress is increasingly used as the preferred strategy to generate 
grafts for HSC transplantation (HSCT), the only curative 
therapeutic option for many hematopoietic malignancies 
as well as non-malignant pathologies. HSCT requires the 
intravenous infusion of a minimum of 2×106 CD34+ stem 
cells/kg recipient body weight; however, a dose of 5×106 CD34+ 
cells/kg is considered preferable for early, consistent, and 
long-term multilineage engraftment116–118. Each failure or delay 
to collect sufficient hematopoietic stem/progenitor cells (HSPCs) 
to proceed to transplantation extends the time of high-dose 
chemotherapy and increases the risk of disease progression in 
cancer patients.
The need to optimize mobilization regimens with regard to their 
stem cell yield, side effects and risk profile, cost-effectiveness, 
and availability for different groups of patients, as well as the 
need to better understand the communication between HSCs 
and their niche, continues to drive mobilization research. In this 
review, we discuss how deciphering the events induced by the 
most commonly used mobilizing agent, granulocyte colony- 
stimulating factor (G-CSF), led to the development of new 
mobilization strategies. We highlight the most recent findings 
and how we envision the newly discovered mobilization 
approaches will impact mobilization in the clinic. Alternative 
applications for mobilization are also reviewed. Lastly, we 
identify open questions and controversies, prospective directions, 
and how recent technical advances can be implemented within 
mobilization research.
Current mobilization regimens
G-CSF-mobilized blood is the preferred graft source for virtually 
all autologous and an increasing majority of allogeneic HSCTs 
owing to its generally higher stem cell content, reduced rates 
of graft failure, and better overall survival as compared to the 
BM2,119,120. After 4–5 days of treatment with G-CSF, circulat-
ing HSPCs increase an average of 50–100-fold121,122 as a result of 
HSPC pool expansion followed by mobilization. The latter is 
achieved through targeting the two major pathways involved in 
stem cell retention: chemokine receptor CXCR4- and integrin 
VLA4-mediated signaling79,123,124. Attenuation of these pathways 
is achieved on the level of gene expression as well as through 
proteolytic cleavage79,123–127. While the role of specific proteases 
involved in the latter, such as neutrophil elastase, cathepsin G, 
and MMP9, remains controversial128,129, the cell surface protease 
dipeptidyl peptidase 4 (DPP-4, CD26), which cleaves and 
inactivates the CXCR4 ligand CXCL12, has indeed been shown 
to be essential for G-CSF-induced mobilization77,78.
Shortcomings of G-CSF such as the slow mode of action17,130, 
side effects, and contraindications131,132 as well as significant 
heterogeneity in the mobilization response121 explain the quest for 
alternative mobilizing agents133. Plerixafor (AMD3100), a small 
molecule bicyclam CXCR4 antagonist, is FDA approved for 
autologous stem cell mobilization in non-Hodgkin’s lymphoma 
and multiple myeloma (MM)134,135. When combined with G-CSF, 
plerixafor increases CD34+ concentration 2–3-fold compared to 
G-CSF alone134,135. However, a significant disadvantage of pler-
ixafor is its cost, adding $25,567 per patient compared to G-CSF 
alone136. Furthermore, up to 24% of patients undergoing  autolo-
gous stem cell transplantation for lymphoma receiving pler-
ixafor and G-CSF still fail to collect ≥2×106 CD34+ cells/kg 
in 4 days of apheresis134,135. A recent economic analysis deter-
mined that reducing apheresis by 1 day can potentially decrease 
medical costs by $6,600137. Thus improved/alternative mobilizing 
agents and strategies are needed.
The long-standing view has been that both HSPC expansion and 
mobilization are necessary for clinically relevant mobilization. 
In line with this view, mobilization with CXCR4 or VLA4 
antagonists alone fails to achieve numbers that would allow their 
use without G-CSF, despite promising potential in preclinical 
models29,61,83,138–140. Very recent findings by our group and others 
challenge this notion and suggest that efficient recruitment of 
long-term, serially repopulating HSCs can be accomplished 
within minutes57,58. Indeed, CXCR4 or VLA4 blockade, when 
combined with the stimulation of a different chemokine recep-
tor, CXCR2, results in extremely rapid and potent HSC mobi-
lization in mice with a repopulating capacity similar or even 
superior to G-CSF-recruited HSCs57,58. These observations show 
that major changes in cellular composition or localization are 
not required for efficient mobilization. They further highlight 
the existence of different HSC species that, upon disruption of 
certain adhesive tethers, can egress from the BM very rapidly with 
kinetics that appear incompatible with a prior requirement for 
changes in gene expression.
The key role of the stromal compartment in G-CSF-induced 
mobilization has long been appreciated124,129,141. Following activa-
tion of their G-CSF receptor, BM monocytes/macrophages, the 
most prominent hematopoietic component of the BM stroma142–144, 
downregulate several retention molecules, including the major 
CXCR4 ligand, CXCL12, and several VLA4 ligands by non- 
hematopoietic stroma, resulting in HSPC egress143,145–147. Absence 
of the G-CSF receptor on monocytes/macrophages abrogates the 
G-CSF-induced mobilization response143, whereas the cytokine 
oncostatin M is thought to mediate communication between 
monocytes and non-hematopoietic stroma145,148. Interestingly, rapid 
mobilizing agents in general, and chemokines and chemokine 
receptor antagonists in particular, are assumed to act on hemat-
opoietic cells directly. Our recent findings challenge this view and 
suggest a critical contribution of stromal (endothelial) CXCR2 
targeting upon rapid HSC mobilization by the combination of 
the CXCR2 ligand truncated Gro-beta (tGro-β) and a VLA4 
antagonist57. Since CXCR2 is absent from the HSPC surface25,26, 
CXCR2-expressing neutrophils have long been assumed to be 
the responding cell. Upon stimulation with CXCR2 agonists, 
neutrophils release proteases that cut adhesive interactions 
between HSPCs and their niche60,76,149,150. Yet CXCR2 within 
stroma was sufficient to induce mobilization with tGro-β and 
a VLA4 antagonist57, pointing towards changes in endothelial 
layer permeability151 as well as crosstalk between endothelia 
and neutrophils as the “priming” events triggered by CXCR2 
activation that boost VLA4 antagonist-induced HSPC egress 
(Figure 2).
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Development of alternative HSPC mobilization 
regimens and grafts
As we continue to learn about the events and mechanisms 
regulating HSPC egress, we approach the ultimate goal of devel-
oping an “optimal” mobilization strategy to collect sufficient 
numbers of primitive stem cells with superior properties within 
a day or two. In contrast to the days when clinical observations 
determined the applicability of a mobilization approach, edu-
cated and targeted designs are becoming the basis for the clinical 
development of mobilizing agents. In addition to the quan-
tity and fitness of the HSPCs, as reflected in their engraftment 
capacity, the immunogenic properties of the graft (i.e. the graft-
versus-host disease [GvHD] profile) are an important feature 
requiring optimization, potentially at the cost of stem cell 
numbers. For example, a substantially reduced incidence of 
GvHD is observed upon transplantation of CXCR4 antagonist- 
mobilized grafts, possibly due to co-mobilization of a specific 
population of dendritic cells (DCs) with immunomodulatory 
properties, plasmacytoid DCs140,152,153. Along the same lines, 
grafts mobilized with pegylated G-CSF were superior to standard 
G-CSF in that they were associated with less GvHD154,155 while 
graft-versus-leukemia (GvL) effects were improved through 
mobilization of invariant natural killer T (iNKT) cells155. Sus-
ceptibility of the mobilized HSPCs to further molecular manipu-
lation, e.g. using gene therapy, is another important criterion 
when defining the “optimal” mobilization strategy. Lastly, if 
proven to be suitable for mobilized HSPCs, recently described 
methods for ex vivo expansion of HSCs156 are expected to shift 
the emphasis on HSPC quality over quantity even further.
Studies with CXCR4 and VLA4 antagonists, tested in VLA4 
and CXCR4 knockout mice, respectively, implied an inde-
pendence between the two axes139,157,158. This suggests that sub-
sets of HSPCs are being retained in the BM by either CXCR4 
or VLA4. Combined with the knowledge of the complex-
ity and multiplicity of events induced in the course of G-CSF 
mobilization129,133, co-existence of these (and possibly other) 
functionally distinct HSPC populations suggests combinato-
rial mobilization approaches as the best alternatives to G-CSF. 
Thus, the small molecule Me6TREN reportedly inhibits CXCR4 
and VLA4 signaling simultaneously, possibly through upregula-
tion of the protease MMP9159. However, given the controversy 
regarding the role of MMP9 for mobilization128, other approaches 
should be explored. In addition to cell-intrinsic HSPC 
retention pathways, disruption of endothelial layer integrity, along 
with the endothelial cell activation and subsequent crosstalk 
between endothelial and mature hematopoietic cells, should 
be included in designing “optimal” mobilization. Recent data 
suggest that Viagra (sildenafil citrate), a phosphodiesterase 
type 5 (PDE5) inhibitor which blocks the degradation of cyclic 
GMP in the smooth muscle cells lining blood vessels, resulting 
in vasodilation, can synergize with plerixafor to rapidly mobilize 
stem cells in mice160.
Various techniques for ex vivo graft manipulation (e.g. T cell 
depletion and CD34 enrichment161–164) have been developed that 
entail extended periods during which the HSPCs stay outside 
of their natural environment and therefore, unsurprisingly, 
exhibit reduced stem cell capacity165,166. From further in-depth 
analyses of differentially mobilized blood (see below), we expect 
to learn not only how to target specific HSPC populations but 
also how to mobilize HSPCs without a concurrent mobilization of 
mature cells, T-cells in particular. In general, a priori cell 
type-specific targeting remains challenging because of the high 
conservation of migratory and retention pathways between 
different hematopoietic cell types. Nevertheless, selective HSPC 
mobilization represents an intriguing goal that would help reduce 
additional graft manipulation.
Figure 2. Mobilization priming effects of CXCR2 stimulation. Upon activation of the CXCR2 receptor on the surface of neutrophils (NE) 
and/or endothelial cells (EC), a reciprocal stimulation of the cells occurs that is critical for the subsequent boost of mobilization with a VLA4 or 
CXCR4 antagonist. Augmented mobilization appears to be a result of increased permeability of the endothelial layer together with other cell 
contact mediated or soluble factors derived from CXCR2-stimulated cells that reduce hematopoietic stem/progenitor cell (HSPC) retention. 
Additional inhibition of the VLA4 or CXCR4 receptor results in efficient targeting of the very primitive, serially repopulating HSPCs retained 
in the bone marrow (BM) primarily via VLA4 or CXCR4 signaling, respectively. The rapid kinetics of CXCR2 agonist + VLA4 or CXCR4 
antagonist-induced mobilization preclude major molecular or cellular changes prior to the BM egress and rather suggest a close proximity of 
the primitive HSPC fraction to the BM sinusoids.
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Mobilization beyond stem cell collection
Chemosensitization
In addition to supplying HSPCs with the factors required for 
their normal development, the BM microenvironment is also a 
refuge for malignant cells, allowing them to escape cytotoxic 
therapies and cause disease relapse167,168. This provides a ration-
ale for targeting the interactions between tumor cells and the BM, 
with the goal of sensitizing them to therapy. Pathways respon-
sible for the anchorage and survival of malignant cells 
and resistance to chemotherapy largely overlap with those of 
normal HSPCs168,169. Accordingly, blockade of CXCR4 and 
VLA4 signaling and/or G-CSF was tested in conjunction with 
chemotherapy in pre-clinical models of acute myeloid leukemia 
(AML170–173), acute174,175 and chronic176 lymphoid leukemia, 
and MM177. Moreover, the FDA-approved CXCR4 antagonist 
plerixafor has been tested as a chemosensitizing agent alone 
and in combination with G-CSF in patients with relapsed 
AML178,179. While the mobilizing capacity varied substantially, an 
overall benefit from adding mobilizing agent(s) to chemotherapy 
has been reported, prolonging survival and decreasing tumor 
burden170,172,177,180 or even eradicating disease175. The benefits of 
this approach in AML and other hematologic malignancies, in 
spite of these preclinical as well as early clinical studies, remain 
both unclear and controversial.
Conditioning
As HSPCs are pharmacologically driven from the BM into 
circulation, the temporarily unoccupied spaces (niches) in theory 
become available to new cells, e.g. the HSPCs introduced into 
a mobilized recipient during transplantation. The utility of 
mobilization for non-cytotoxic and on-target conditioning prior 
to HSCT is supported by the fact that mobilized cells return to 
the BM after spending some time in peripheral circulation, as 
shown in studies of parabiotic mice181. Yet virtually all attempts 
at mobilization alone for conditioning of an adult host before 
HSCT have been unsuccessful (Karpova and Rettig, unpub-
lished data). It is unclear whether the reason is that the cells 
introduced exogenously are inherently disadvantaged (less fit?) 
compared with endogenously circulating HSPCs or whether 
the mobilizing agent interferes with the repopulating capacity 
of the transplanted cells. An intriguing alternative explanation 
is that owing to targeting/recruitment of a specific population 
during the mobilization process, and by extension because of 
emptying of very specific niches, only HSPCs mobilized with 
the same mobilizing regimen are able to engraft BM niches that 
become available. Interestingly, since BM- or fetal liver-derived 
HSPCs have been used to engraft mobilized recipients (Karpova 
and Rettig, unpublished data), the possibility that a qualita-
tive rather than quantitative approach might lead to success-
ful, persistent engraftment is untested. Given recent reports of 
successful conditioning using antibody–drug conjugates target-
ing the pan leukocyte marker CD45182 and the CD117-targeting 
antibodies183–185, or a cocktail of monoclonal antibodies deplet-
ing CD47-expressing cells along with T cells, NK cells, 
and HSPCs186, mobilization-based conditioning may not be 
a promising approach in postnatal recipients. However, fetal 
HSPC mobilization with a VLA4 antagonist followed by 
in utero HSCT results in increased donor HSC homing to the fetal 
liver and enhanced long-term allogeneic engraftment in mice187. 
Therefore, mobilization-based conditioning regimens might be 
applicable for in utero HSCT.
Gene therapy
Manipulating HSCs to correct mutations that cause inherited 
diseases of the hematopoietic system such as sickle cell anemia 
and beta-thalassemia represents a potential cure, with recent 
advances in gene therapeutic approaches (CRISPR-Cas9, 
TALEN, and ZFN)188–193 allowing sustainable correction of the 
genetic defects. Autologous HSCT is the method of choice in this 
setting, whereby instead of extracting HSCs for subsequent 
ex vivo manipulation, stem cells are mobilized into the 
circulation and subjected to gene therapy in situ194–196. As 
discussed above, HSC collection and ex vivo editing inevitably 
leads to a diminished stem cell capacity, which can be avoided 
by editing the cells in the peripheral blood. Proof of principle 
for mobilization-based gene therapy was reported following 
mobilization with G-CSF plus a CXCR4 antagonist, with sus-
tained expression of the introduced transgene over a period 
of 5 months196. We believe this approach should be developed 
further, e.g. by using it in combination with mobilization 
strategies to preferentially recruit stem cells with superior 
repopulating capacity into the circulation. In addition, these 
cells may be more susceptible to therapeutic gene editing. 
Apart from its obvious therapeutic benefit, this approach might 
become useful for studying functional differences between HSCs 
that have been mobilized into the circulation and returned to 
the BM and HSCs that remain in the BM niche.
Biology of the hematopoietic niche
The discovery of compounds and pathways that enable HSPC 
displacement from the niche has provided important insights 
into the regulation of HSPC trafficking and maintenance. For 
example, detailed analysis of the mechanisms underlying 
G-CSF-induced mobilization was indispensable for establishing 
monocytes/macrophages as crucial components of the BM niche 
and understanding their crosstalk with the non-hematopoietic 
stroma143,145–147. More recent studies demonstrated that bone 
marrow dendritic cells regulate endothelial cell function in part 
through CXCR2 signaling, resulting in HSPC mobilization 
and loss of bone marrow macrophages151. Similarly, studies with 
the CXCR2 ligand tGro-β disclosed the role of another mature 
leukocyte population, neutrophils, in HSPC trafficking57,58,76. 
Together with the observation that the circadian release of 
HSPCs into the circulation is synchronized by daily return of 
aged neutrophils from the circulation into the BM197, these 
findings implicate neutrophils as critical mediators of HSPC 
localization at steady state and upon enforced egress. On the 
molecular level, the recognition that all physiological, patho-
logical, and pharmacological mobilization stimuli described 
to date interfere with VLA4 or CXCR4 signaling or both 
(Figure 1) highlights the key roles of these two pathways in 
HSPC trafficking.
Open questions and future directions
Homeostatic HSPC trafficking
The physiological function and regulation of daily HSPC egress 
remain elusive. We know that, similar to their mature coun-
terparts, the release of HSPCs from the BM follows a circadian 
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rhythm11,94,198, with sympathetic nervous system-derived adren-
ergic signals acting through beta(3)-adrenergic receptors on 
BM stroma to downregulate CXCL12 signaling (and therefore 
retention10,11). While we understand the purpose of migration of 
more differentiated hematopoietic cells out of the BM to undergo 
maturation, encounter antigens, proliferate, etc., the role(s) of 
HSPCs found in blood and other peripheral tissues is specula-
tive. Exchange between different parts of the hematopoietic 
system has been suggested to be mediated by homeostatic 
HSPC migration7,133 and is supported by observations from 
parabiotic9,199,200 as well as partially irradiated201,202 mice. An 
alternative explanation implies a possible immune surveillance 
function of HSPCs that have also been found in the lymphoid 
system203 and non-hematopoietic tissues with crucial immune 
functions such as the intestine204. Furthermore, expression of 
MHC class II molecules, otherwise restricted to professional 
antigen-presenting cells, has been detected in HSPCs205,206.
Prediction of HSPC mobilization success and failure
With regard to inadequate HSPC mobilization, one must 
distinguish between disease- and/or treatment-associated failure 
and failure of G-CSF mobilization in healthy donors. Of note, 
less than 1% of “healthy allogeneic donors” fail to collect an 
optimal (5×106 CD34/kg) or minimal (2×106 CD34/kg) amount 
of CD34+ cells after a standard 4–5-day regimen of G-CSF 
mobilization133. This relatively uncommon event may represent 
the extreme heterogeneity of HSPC mobilization seen among 
the general population with no known medical conditions or 
prior exposure to chemotherapy or radiation. Thus, CD34 counts 
between 5 and 500 cells per µl blood have been reported121. 
The general consensus, derived from studies of poor- and well- 
mobilizing mouse strains207,208, as well as repetitive mobiliza-
tion of healthy donors121,209, is that genetic factors determine the 
mobilization response in healthy individuals. However, single 
nucleotide polymorphisms in any of the obvious candidate 
genes (including CXCL12210, VCAM1211,212, and CD44212,213) do 
not correlate with mobilization efficacy in response to G-CSF or 
plerixafor in larger population studies133,214,215. Knowledge of 
high or low HSPC mobilization potential could be translated into 
donor screening prior to mobilization to help predict response 
and potentially to guide the best mobilization strategy.
The probability of mobilization failure in patients directly 
correlates with the amount and extent of prior cytotoxic 
exposure216–218. Other clinical and demographic features of normal 
donors and patients undergoing autologous stem cell mobilization 
that predict poor mobilization include age217,219, resting platelet 
counts217,220, and a history of diabetes mellitus221. Failure rates 
have decreased since the CXCR4 antagonist plerixafor was 
approved for the mobilization of HSPCs for MM and non-
Hodgkin lymphoma patients when given in conjunction with 
G-CSF133–135. However, given that the diminished mobilization 
response results from the substantially reduced HSPC pool in 
these patients222, approaches that both potently expand HSPCs and 
induce their egress into the circulation are needed. We recently 
reported that the administration of CXCR4 antagonists to mice 
by subcutaneous continuous infusion for 1–4 weeks induces a 
robust mobilization response that significantly exceeds the 
mobilization achieved with bolus drug injections and was 
25–50-fold greater than a 5-day course of G-CSF158. Moreover, 
continuous infusion of CXCR4 inhibitors leads to a two- to 
four-fold expansion of the HSPC pool in the bone marrow that 
exhibits a distinct repopulating advantage when tested in serial 
competitive transplantation experiments. Similarly, others have 
shown that the FMS-like tyrosine kinase 3 ligand (Flt3L) 
stimulates the expansion and mobilization of HSPCs in animals 
and humans223–225.
Profiling of differentially mobilized blood
Gene expression profiling of the HSPC populations mobi-
lized with different agents has been performed, mostly using 
microarrays57,226. Not unexpectedly, increased relative expres-
sion of genes involved in lymphoid development were detected 
in grafts mobilized with a CXCR4 antagonist alone and in 
conjunction with G-CSF as compared to G-CSF alone226. A closer 
similarity between BM-resident and CXCR4 antagonist- 
mobilized HPSCs as compared to BM-resident versus G-CSF-
mobilized HSPCs had been proposed to be due to the fast 
kinetics of CXCR4 antagonist-induced mobilization. However, 
the opposite was detected when comparing the three, with BM- 
resident HSPCs showing a profile much closer to that of 
G-CSF-mobilized HSPCs57. It would appear from these studies 
that CXCR4 disruption recruits a specific rather than representa-
tive fraction of the BM HSPCs. By contrast, VLA4 antagonist 
+ tGro-β-mobilized HSPCs have a profile very similar to that 
of BM-resident as well as G-CSF-mobilized HSPCs, indicat-
ing that rapid kinetics of mobilization can indeed be associated 
with an HSPC profile closely related to BM-resident HSPCs57.
Single cell RNA sequencing (scRNA-seq) is currently revolu-
tionizing the field of hematopoietic cancer research by defining 
the heterogeneity of malignant cells and the supporting network 
of non-malignant cells227–230. Naturally, scRNA-seq analysis and 
comparison of differentially mobilized HSPCs will provide 
key insights and may strengthen the notion that they are com-
prised of different HSPC subsets rather than representing a 
homogenous population with an overall altered expression 
profile depending on the agent used. Moreover, we anticipate 
that concurrent analysis of peripheral blood and BM HSPC 
compartments will shed new light on the unique identity and 
specific origin of mobilized cells that respond to specific 
mobilizing agents. In general, single cell characterization of 
mobilized blood/HSPCs is expected to be particularly informa-
tive with rapid-mobilizing agents, where the kinetics of the 
cell recruitment would not allow for major changes of the cell 
identity or localization prior to BM egress.
Interestingly, despite the more elaborate isolation process for 
non-hematopoietic as opposed to hematopoietic cells, a detailed 
characterization of the stromal populations using single cell 
approaches has been published already231–233. However, the 
contribution of the newly identified populations to HSPC 
retention remains unexplored. Ultimately, simultaneous analysis 
of stroma and HSPCs based on their proximity using spatial 
transcriptomics promises to reveal potentially unique relation-
ships between certain stromal and hematopoietic cell types and 
thereby define the biological roles of the long-argued diversity 
within the hematopoietic niche.
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Summary
Pharmacologically induced egress of HSPCs from the BM has 
become an indispensable tool in HSCT with all autologous and 
over 80% of allogeneic transplants performed with mobilized 
blood. Mechanistic insights gained from studying the complex 
chain of events induced during mobilization with G-CSF have 
paved the way for the rational design of alternative mobilization 
approaches without the inherent shortcomings of G-CSF such as 
slow mode of action and side effects. Similar to the recruitment 
of healthy HSPCs into the circulation, targeting of various BM 
retention pathways has been explored as a means to sensitize 
leukemic cells and thereby improve the efficacy of chemo-
therapy. Moreover, mobilization of HSPCs as a non-cytotoxic 
conditioning strategy as well as for gene therapy represents 
two other applications of mobilization beyond mere collection 
of a stem cell graft. Understanding the physiological function 
of homeostatic HSPC trafficking and identifying the genetic 
determinants of mobilization efficiency, along with character-
izing the differentially mobilized HSPC populations on a single 
cell level, represent some of the directions of future mobilization 
research.
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